Drugs Made In America Acquisition Corp. Units (DMAAU) - Total Assets
Based on the latest financial reports, Drugs Made In America Acquisition Corp. Units (DMAAU) holds total assets worth $239.92 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Drugs Made In America Acquisition Corp. Units - Total Assets Trend (2024–2025)
This chart illustrates how Drugs Made In America Acquisition Corp. Units's total assets have evolved over time, based on quarterly financial data. Also see market value of Drugs Made In America Acquisition Corp. for the company's overall valuation and market capitalisation.
Drugs Made In America Acquisition Corp. Units - Asset Composition Analysis
Current Asset Composition (December 2025)
Drugs Made In America Acquisition Corp. Units's total assets of $239.92 Million consist of 0.0% current assets and 100.0% non-current assets. Review total liabilities of Drugs Made In America Acquisition Corp. to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how Drugs Made In America Acquisition Corp. Units's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See DMAAU stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Drugs Made In America Acquisition Corp. Units's current assets represent 0.0% of total assets in 2025, a decrease from 906.1% in 2024.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2025, down from 245.3% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2024.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Drugs Made In America Acquisition Corp. Units Competitors by Total Assets
Key competitors of Drugs Made In America Acquisition Corp. Units based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
New Providence Acquisition Corp. III Class A Ordinary Shares
NASDAQ:NPAC
|
USA | $310.81 Million |
|
Live Oak Acquisition Corp. V Class A Ordinary Shares
NASDAQ:LOKV
|
USA | $240.47 Million |
|
OneIM Acquisition Corp. Class A Ordinary Shares
NASDAQ:OIM
|
USA | $293.03 Million |
|
ProCap Acquisition Corp Class A Ordinary Shares
NASDAQ:PCAP
|
USA | $261.20 Million |
|
Jackson Acquisition Company II
NYSE:JACS
|
USA | $245.21 Million |
|
Graf Global Corp
NYSE MKT:GRAF
|
USA | $243.44 Million |
|
Pyrophyte Acquisition Corp. II
NYSE:PAII
|
USA | $206.36 Million |
|
SPACSphere Acquisition Corp. Class A Ordinary Shares
NASDAQ:SSAC
|
USA | $175.44 Million |
Drugs Made In America Acquisition Corp. Units - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.03 | 0.20 | 0.37 |
| Quick Ratio | 0.03 | 0.20 | 0.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-363.98K | $-276.35K | $-132.89 |
Drugs Made In America Acquisition Corp. Units - Advanced Valuation Insights
This section examines the relationship between Drugs Made In America Acquisition Corp. Units's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 1.29 |
| Asset Growth Rate (YoY) | 43556569.5% |
| Total Assets | $239.92 Million |
| Market Capitalization | $308.64 Million USD |
Valuation Analysis
Above Book Valuation: The market values Drugs Made In America Acquisition Corp. Units's assets above their book value (1.29x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Drugs Made In America Acquisition Corp. Units's assets grew by 43556569.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Drugs Made In America Acquisition Corp. Units (2024–2025)
The table below shows the annual total assets of Drugs Made In America Acquisition Corp. Units from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $239.92 Million | +43556569.51% |
| 2024-12-31 | $550.82 | -- |
About Drugs Made In America Acquisition Corp. Units
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.